@article{PickhardSieglBaumannetal.2014,
  author    = {Pickhard, Anja and Siegl, Michael and Baumann, Alexander and Huhn, Maximilian and Wirth, Markus and Reiter, Rudolf and Rudelius, Martina and Piontek, Guido and Brockhoff, Gero},
  title     = {The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism},
  series = {Oncotarget},
  volume    = {5},
  journal   = {Oncotarget},
  number    = {14},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120757},
  pages     = {5428-38},
  year      = {2014},
  abstract  = {Objectives: The aim of this study was to evaluate the efficiency of cetuximab-based anti-EGFR treatment and Aurora kinase A / B knockdown as a function of Aurora kinase polymorphism in HNSCC cell lines. Materials and methods: First, protein expression of Aurora kinase A / B and EGFR and Aurora kinase A polymorphism were studied in tumour samples. The survival and proliferation of Aurora kinase A homo- (Cal27) and heterozygous (HN) HNSCC cell lines was evaluated using a colony formation assay and a flow cytometric assay. Also, aneuploidy was determined. EGFR signalling pathway were visualised by western blotting. Results: Immunohistochemistry revealed the overexpression of Aurora kinase A / B in HNSCC. The knockdown of each kinase caused a significant decrease in clonogenic survival, independent of Aurora kinase A polymorphism. In contrast, cetuximab treatment impaired clonogenic survival only in the Aurora kinase A-homozygous cell line (Cal27). Conclusion: This study provides in vitro evidence for the predictive value of Aurora kinase A polymorphism in the efficiency of cetuximab treatment. Resistance to cetuximab treatment can be overcome by simultaneous Aurora kinase A/B knockdown.},
  language  = {en}
}